Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2013 1
2019 1
2020 3
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
Lin MP, Meschia JF, Gopal N, Barrett KM, Ross OA, Ertekin-Taner N, Brott TG. Lin MP, et al. J Stroke Cerebrovasc Dis. 2021 Mar;30(3):105581. doi: 10.1016/j.jstrokecerebrovasdis.2020.105581. Epub 2020 Dec 31. J Stroke Cerebrovasc Dis. 2021. PMID: 33388632
We aimed to conduct a systematic review and meta-analysis to estimate the efficacy and safety of cilostazol compared to aspirin for stroke prevention in patients with previous stroke or transient ischemic attack (TIA) …
We aimed to conduct a systematic review and meta-analysis to estimate the efficacy and safety of cilostazol …
Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis.
McHutchison C, Blair GW, Appleton JP, Chappell FM, Doubal F, Bath PM, Wardlaw JM. McHutchison C, et al. Stroke. 2020 Aug;51(8):2374-2385. doi: 10.1161/STROKEAHA.120.029454. Epub 2020 Jul 10. Stroke. 2020. PMID: 32646330 Free PMC article.
In addition to weak antiplatelet effects, it stabilizes endothelium, aids myelin repair and astrocyte-neuron energy transfer in laboratory models, effects that may be beneficial in preventing small vessel disease progression. METHODS: A systematic review and …
In addition to weak antiplatelet effects, it stabilizes endothelium, aids myelin repair and astrocyte-neuron energy transfer in laboratory m …
Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke.
Dinicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH, Bangalore S, Messerli FH. Dinicolantonio JJ, et al. Am J Cardiol. 2013 Oct 15;112(8):1230-4. doi: 10.1016/j.amjcard.2013.05.067. Epub 2013 Jul 2. Am J Cardiol. 2013. PMID: 23827403 Review.
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol, an antiplatelet and vasodilating agent, has shown promise for the secondary prevention of stroke. ...
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol …
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
Kamal AK, Naqvi I, Husain MR, Khealani BA. Kamal AK, et al. Cochrane Database Syst Rev. 2011 Jan 19;2011(1):CD008076. doi: 10.1002/14651858.CD008076.pub2. Cochrane Database Syst Rev. 2011. PMID: 21249700 Free PMC article. Review.
BACKGROUND: Aspirin is widely used for secondary prevention after stroke. Cilostazol has shown promise as an alternative to aspirin in Asian people with stroke. ...AUTHORS' CONCLUSIONS: Cilostazol is more effective than a …
BACKGROUND: Aspirin is widely used for secondary prevention after stroke. Cilostazol has shown promise as …
Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.
Geeganage C, Wilcox R, Bath PM. Geeganage C, et al. BMC Med. 2010 Jun 16;8:36. doi: 10.1186/1741-7015-8-36. BMC Med. 2010. PMID: 20553581 Free PMC article. Review.
BACKGROUND: Dual antiplatelet therapy is usually superior to mono therapy in preventing recurrent vascular events (VEs). This systematic review assesses the safety and efficacy of triple antiplatelet therapy in comparison with dual therapy in reducing recurre …
BACKGROUND: Dual antiplatelet therapy is usually superior to mono therapy in preventing recurrent vascular events (VEs). This syst …
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A. Bala MM, et al. Cochrane Database Syst Rev. 2020 Oct 12;10(10):CD012169. doi: 10.1002/14651858.CD012169.pub3. Cochrane Database Syst Rev. 2020. PMID: 33045766 Free PMC article.
OBJECTIVES: To assess the effects of antiplatelet (AP) or anticoagulant agents, or both, for the secondary prevention of recurrent thrombosis, particularly ischemic stroke, in people with APS. ...One of the above-mentioned studies was a three-armed study that …
OBJECTIVES: To assess the effects of antiplatelet (AP) or anticoagulant agents, or both, for the secondary prevention of recur …
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Kim SM, Jung JM, Kim BJ, Lee JS, Kwon SU. Kim SM, et al. Stroke. 2019 Dec;50(12):3503-3511. doi: 10.1161/STROKEAHA.119.026655. Epub 2019 Oct 14. Stroke. 2019. PMID: 31607242
Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet the …
Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of …
Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.
Robertson L, Ghouri MA, Kovacs F. Robertson L, et al. Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD002071. doi: 10.1002/14651858.CD002071.pub3. Cochrane Database Syst Rev. 2012. PMID: 22895926 Free PMC article. Review.
At 12 months post intervention, no statistically significant difference in reocclusion/restenosis was detected for any of the following comparisons: high-dose ASA versus low-dose ASA (OR 0.98, 95% CI 0.64 to 1.48; P = 0.91), ASA/DIP versus vitamin K antagonists (VKA …
At 12 months post intervention, no statistically significant difference in reocclusion/restenosis was detected for any of the following comp …
Antithrombotic treatment after stroke due to intracerebral haemorrhage.
Cochrane A, Chen C, Stephen J, Rønning OM, Anderson CS, Hankey GJ, Al-Shahi Salman R. Cochrane A, et al. Cochrane Database Syst Rev. 2023 Jan 26;1(1):CD012144. doi: 10.1002/14651858.CD012144.pub3. Cochrane Database Syst Rev. 2023. PMID: 36700520 Free PMC article. Review.
We grouped RCTs separately for analysis according to 1) the class(es) of antithrombotic treatment used for the intervention and comparator, and 2) the duration of antithrombotic treatment use (short term versus long term). We pooled the intention-to-treat populations of RC …
We grouped RCTs separately for analysis according to 1) the class(es) of antithrombotic treatment used for the intervention and comparator, …